ARS Pharmaceuticals Net Income
| SPRY Stock | 8.85 0.04 0.45% |
As of the 18th of February 2026, ARS Pharmaceuticals shows the risk adjusted performance of 0.0283, and Mean Deviation of 3.79. Relative to fundamental indicators, the technical analysis model gives you tools to check practical technical drivers of ARS Pharmaceuticals, as well as the relationship between them.
ARS Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 4.7934 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 7.2 M | 7.6 M | |
| Net Income From Continuing Ops | 7.2 M | 7.6 M | |
| Net Loss | -31.2 M | -29.7 M | |
| Net Income Per Share | 0.07 | 0.08 | |
| Net Income Per E B T | 0.87 | 0.78 |
ARS | Net Income | Build AI portfolio with ARS Stock |
The evolution of Net Income for ARS Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how ARS Pharmaceuticals compares to historical norms and industry peers.
Latest ARS Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of ARS Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in ARS Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of ARS Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is ARS Pharmaceuticals' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ARS Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 8 M | 10 Years Trend |
|
Net Income |
| Timeline |
ARS Net Income Regression Statistics
| Arithmetic Mean | (15,869,335) | |
| Geometric Mean | 14,675,795 | |
| Coefficient Of Variation | (97.32) | |
| Mean Deviation | 10,019,606 | |
| Median | (17,579,000) | |
| Standard Deviation | 15,444,689 | |
| Sample Variance | 238.5T | |
| Range | 62.4M | |
| R-Value | 0.24 | |
| Mean Square Error | 240.3T | |
| R-Squared | 0.06 | |
| Significance | 0.36 | |
| Slope | 721,336 | |
| Total Sum of Squares | 3816.6T |
ARS Net Income History
Other Fundumenentals of ARS Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
ARS Pharmaceuticals Net Income component correlations
ARS Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for ARS Pharmaceuticals is extremely important. It helps to project a fair market value of ARS Stock properly, considering its historical fundamentals such as Net Income. Since ARS Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ARS Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ARS Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ARS Pharmaceuticals. If investors know ARS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ARS Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.81) | Revenue Per Share | Quarterly Revenue Growth 14.716 | Return On Assets | Return On Equity |
Understanding ARS Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects ARS's accounting equity. The concept of intrinsic value - what ARS Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push ARS Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between ARS Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ARS Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, ARS Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
ARS Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ARS Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ARS Pharmaceuticals.
| 11/20/2025 |
| 02/18/2026 |
If you would invest 0.00 in ARS Pharmaceuticals on November 20, 2025 and sell it all today you would earn a total of 0.00 from holding ARS Pharmaceuticals or generate 0.0% return on investment in ARS Pharmaceuticals over 90 days. ARS Pharmaceuticals is related to or competes with GH Research, Nanobiotix, Arbutus Biopharma, LENZ Therapeutics, Savara, Rezolute, and Kura Oncology. ARS Pharmaceuticals is entity of United States More
ARS Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ARS Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ARS Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.54 | |||
| Information Ratio | 0.0151 | |||
| Maximum Drawdown | 32.13 | |||
| Value At Risk | (7.26) | |||
| Potential Upside | 8.29 |
ARS Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ARS Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ARS Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use ARS Pharmaceuticals historical prices to predict the future ARS Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0283 | |||
| Jensen Alpha | 0.093 | |||
| Total Risk Alpha | (0.17) | |||
| Sortino Ratio | 0.0179 | |||
| Treynor Ratio | 0.171 |
ARS Pharmaceuticals February 18, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0283 | |||
| Market Risk Adjusted Performance | 0.181 | |||
| Mean Deviation | 3.79 | |||
| Semi Deviation | 4.34 | |||
| Downside Deviation | 4.54 | |||
| Coefficient Of Variation | 4014.47 | |||
| Standard Deviation | 5.39 | |||
| Variance | 29.04 | |||
| Information Ratio | 0.0151 | |||
| Jensen Alpha | 0.093 | |||
| Total Risk Alpha | (0.17) | |||
| Sortino Ratio | 0.0179 | |||
| Treynor Ratio | 0.171 | |||
| Maximum Drawdown | 32.13 | |||
| Value At Risk | (7.26) | |||
| Potential Upside | 8.29 | |||
| Downside Variance | 20.57 | |||
| Semi Variance | 18.81 | |||
| Expected Short fall | (4.60) | |||
| Skewness | 0.8795 | |||
| Kurtosis | 2.65 |
ARS Pharmaceuticals Backtested Returns
ARS Pharmaceuticals appears to be moderately volatile, given 3 months investment horizon. ARS Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.11, which signifies that the company had a 0.11 % return per unit of risk over the last 3 months. By analyzing ARS Pharmaceuticals' technical indicators, you can evaluate if the expected return of 0.6% is justified by implied risk. Please makes use of ARS Pharmaceuticals' mean deviation of 3.79, and Risk Adjusted Performance of 0.0283 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, ARS Pharmaceuticals holds a performance score of 8. The firm shows a Beta (market volatility) of 0.73, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, ARS Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding ARS Pharmaceuticals is expected to be smaller as well. Please check ARS Pharmaceuticals' value at risk, kurtosis, market facilitation index, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether ARS Pharmaceuticals' price patterns will revert.
Auto-correlation | -0.66 |
Very good reverse predictability
ARS Pharmaceuticals has very good reverse predictability. Overlapping area represents the amount of predictability between ARS Pharmaceuticals time series from 20th of November 2025 to 4th of January 2026 and 4th of January 2026 to 18th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ARS Pharmaceuticals price movement. The serial correlation of -0.66 indicates that around 66.0% of current ARS Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.66 | |
| Spearman Rank Test | -0.84 | |
| Residual Average | 0.0 | |
| Price Variance | 0.77 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
ARS Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, ARS Pharmaceuticals reported net income of 8 M. This is 97.66% lower than that of the Biotechnology sector and 88.58% lower than that of the Health Care industry. The net income for all United States stocks is 98.6% higher than that of the company.
ARS Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ARS Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ARS Pharmaceuticals could also be used in its relative valuation, which is a method of valuing ARS Pharmaceuticals by comparing valuation metrics of similar companies.ARS Pharmaceuticals is currently under evaluation in net income category among its peers.
ARS Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of ARS Pharmaceuticals from analyzing ARS Pharmaceuticals' financial statements. These drivers represent accounts that assess ARS Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ARS Pharmaceuticals' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 192.3M | 340.8M | 521.8M | 1.0B | 1.2B | 810.8M | |
| Enterprise Value | 141.3M | 130.8M | 451.1M | 971.9M | 1.1B | 723.5M |
ARS Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ARS Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ARS Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
ARS Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in ARS Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of ARS Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ARS Pharmaceuticals' value.| Shares | Southpoint Capital Advisors Lp | 2025-06-30 | 1.7 M | Fmr Inc | 2025-06-30 | 1.6 M | Aberdeen Group Plc | 2025-06-30 | 1.5 M | Goldman Sachs Group Inc | 2025-06-30 | 1.5 M | Wellington Management Company Llp | 2025-06-30 | 1.4 M | Octagon Capital Advisors Lp | 2025-06-30 | 1.4 M | Geode Capital Management, Llc | 2025-06-30 | 1.3 M | Mpm Oncology Impact Management Lp | 2025-06-30 | 1.3 M | Rubric Capital Management Lp | 2025-06-30 | 1.3 M | Ra Capital Management, Llc | 2025-06-30 | 10.9 M | Deerfield Management Co | 2025-06-30 | 9.7 M |
ARS Fundamentals
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (0.56) % | ||||
| Operating Margin | (1.64) % | ||||
| Current Valuation | 684.36 M | ||||
| Shares Outstanding | 98.85 M | ||||
| Shares Owned By Insiders | 16.82 % | ||||
| Shares Owned By Institutions | 93.90 % | ||||
| Number Of Shares Shorted | 21.4 M | ||||
| Price To Book | 5.92 X | ||||
| Price To Sales | 6.13 X | ||||
| Revenue | 89.15 M | ||||
| Gross Profit | 114.87 M | ||||
| EBITDA | (3 M) | ||||
| Net Income | 8 M | ||||
| Total Debt | 42 K | ||||
| Book Value Per Share | 1.49 X | ||||
| Cash Flow From Operations | 13.55 M | ||||
| Short Ratio | 12.05 X | ||||
| Earnings Per Share | (0.81) X | ||||
| Target Price | 28.83 | ||||
| Number Of Employees | 162 | ||||
| Beta | 0.74 | ||||
| Market Capitalization | 874.81 M | ||||
| Total Asset | 351.15 M | ||||
| Retained Earnings | (123.31 M) | ||||
| Working Capital | 310.86 M | ||||
| Net Asset | 351.15 M |
About ARS Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ARS Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ARS Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ARS Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for ARS Stock Analysis
When running ARS Pharmaceuticals' price analysis, check to measure ARS Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARS Pharmaceuticals is operating at the current time. Most of ARS Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ARS Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARS Pharmaceuticals' price. Additionally, you may evaluate how the addition of ARS Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.